Embed Size (px)
Citation preview
Covered in this Report
• This report covers the present scenario and the growth prospects of the global fibromyalgia drugs market for 2015-2019.
• To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of fibromyalgia.
• Technavio's report, the Global Fibromyalgia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.
Global Fibromyalgia Drugs Market 2015-
2019
USA – CANADA – UK – CHINA – INDIA
Market Overview• According to the National Institute of Arthritis and
Musculoskeletal and Skin Diseases, fibromyalgia is a syndrome with an unknown cause and chronic pain and muscle tenderness as the major symptoms.
• Unlike arthritis, it does not cause joint, muscle or other tissue inflammation.
• However, fibromyalgia is known to cause impairment of joints, soft tissues, and causes significant pain and fatigue.
• Fibromyalgia affects women more than men.
• Currently in the US, only three drugs are approved to treat fibromyalgia.
• Technavio's analysts forecast the global fibromyalgia drugs market to grow at a CAGR of 0.79% over the period 2014-2019.
To know more aboutGlobal Fibromyalgia Drugs Market 2015-
2019,please mail us at
USA – CANADA – UK – CHINA – INDIA
Key Vendors and Regions
• Actavis
• Eli Lilly
• Pfizer
• Daiichi Sankyo
• Innovative Med Concepts
• Meda
• Meiji Seika
• Merck Sharp and Dohme
View Our Report: Global Fibromyalgia Drugs Market
2015-2019
• Americas
• APAC
• EMEA
Vendors Regions
USA – CANADA – UK – CHINA – INDIA
Key Findings
USA – CANADA – UK – CHINA – INDIA
• Pharmaceutical companies carry out small molecular changes on existing drugs and market them as me-too drugs.
• Vendors produce me-too drugs because of the increased expenditure associated with drug development and to overcome cost barriers.
• The National Fibromyalgia and Chronic Pain Association in the US and various global nongovernmental trusts for fibromyalgia celebrate May 12th every year as Fibromyalgia Awareness Day.
• Co-development agreements enable the use of the technical expertise of both companies for mutual benefits.
• They also allow the use of the regulatory and developmental experience gained by one company to support the pipeline candidates of the other and ensure the inflow of adequate funds for R&D.
Key Questions Answered in Our Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Have a question of your own about this report?
Ask our Analysts
USA – CANADA – UK – CHINA – INDIA
• Decision makers and influencers in sales & marketing, strategy, product and R&D teams rely on research from Technavio. We have a large and growing base of happy customers worldwide. Our customers include technology suppliers, end users, consulting companies, investment firms and research institutes.
• Technavio was founded in 2003 in London. We have about 300 analysts globally. We cover more than 500 technologies across 80 countries. Traditional media such as Forbes Asia and New York Times, along with other web media portals, like to quote us.
About Technavio
Some of our clients include:ACT Global, Flextronics, Huawei Technologies Co, Infosys, Harris Corporation, Infosys, Intercad, Hidaka Precision Tools & Dies Company, Huawei Technologies Co, American Capital, Analysis Group, Netscout, NTT DoCoMo
USA – CANADA – UK – CHINA – INDIA
View Our Report
Global Fibromyalgia Drugs Market 2015-2019
75 Pages | SKU: IRTNTR6480
For media enquiries,
please drop us a mail at
For more on the scope of the report, mail us at
Thank You!
Mail us at: [email protected] can visit us at:www.technavio.com
USA – CANADA – UK – CHINA – INDIA
